Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Zanidatamab: Detailed Review of its Transformative R&D Success
30 September 2023
This article summarized the latest R&D progress of Zanidatamab, the Mechanism of Action for Zanidatamab, and the drug target R&D trends for Zanidatamab.
Drug Insights
4 min read
Sulfathiazole Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
28 September 2023
This article summarized the latest R&D progress of Sulfathiazole, the Mechanism of Action for Sulfathiazole, and the drug target R&D trends for Sulfathiazole.
Latest Hotspot
3 min read
BMS reports improved survival in operable non-small cell lung cancer patients with a regimen of Opdivo (nivolumab) and chemotherapy
28 September 2023
Bristol Myers Squibb states that a pre/postoperative regimen of Opdivo (nivolumab) and chemotherapy significantly improves survival in operable non-small cell lung cancer patients.
Drug Insights
4 min read
Unleashing the Power of Streptozocin: A Comprehensive Review on R&D Breakthroughs
28 September 2023
This article summarized the latest R&D progress of Streptozocin, the Mechanism of Action for Streptozocin, and the drug target R&D trends for Streptozocin.
"What" Series
2 min read
What is ICF in Life Sciences?
28 September 2023
ICF stands for Informed Consent Form, which is a document proof that each participant voluntarily participates in a certain experiment.
Drug Insights
4 min read
A Comprehensive Review of Stiripentol's R&D Innovations and Drug Target Mechanism
28 September 2023
This article summarized the latest R&D progress of Stiripentol, the Mechanism of Action for Stiripentol, and the drug target R&D trends for Stiripentol.
Latest Hotspot
3 min read
Inmagene created Celexor Bio, based on its anti-ILT7 mAb displaying enhanced pDC reduction capabilities
28 September 2023
Inmagene has established Celexor Bio, which is premised on its anti-ILT7 mAb that demonstrates improved pDC reduction capabilities.
Drug Insights
4 min read
Pharmaceutical Insights: Sintilimab's R&D Progress and its Mechanism of Action on Drug Target
28 September 2023
This article summarized the latest R&D progress of Sintilimab, the Mechanism of Action for Sintilimab, and the drug target R&D trends for Sintilimab.
"What" Series
2 min read
What is Protocol in Life Sciences?
28 September 2023
A protocol outlines the experiment's context, theory, and intent, its design, methodology, and structure including statistical considerations, and the conditions for execution and completion.
Drug Insights
4 min read
Exploring Sargramostim's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
28 September 2023
This article summarized the latest R&D progress of Sargramostim, the Mechanism of Action for Sargramostim, and the drug target R&D trends for Sargramostim.
Latest Hotspot
3 min read
The Phase 3 TROPION-Breast01 trial showed Datopotamab Deruxtecan significantly improved progression-free survival in patients with HR positive, HER2 low/negative breast cancer
28 September 2023
The Phase 3 TROPION-Breast01 trial showed that Datopotamab Deruxtecan significantly improved progression-free survival for patients with HR positive, HER2 low or negative breast cancer.
Drug Insights
4 min read
Decoding Rocuronium Bromide: A Comprehensive Study of its R&D Trends
28 September 2023
This article summarized the latest R&D progress of Rocuronium Bromide, the Mechanism of Action for Rocuronium Bromide, and the drug target R&D trends for Rocuronium Bromide.